SCPSScopus Biopharma, Inc.

About Scopus Biopharma, Inc. (SCPS)

Scopus Biopharma, Inc. (SCPS) is a Biotechnology company headquartered in New York, NY, United States whose shares trade over-the-counter on the Expert Market tier.

Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. We are currently focusing our development efforts on our immuno-oncology programs, which are conducted primarily through Duet BioTherapeutics Inc. ("Duet"), our majority-owned subsidiary. These programs include three distinctive complementary CpG-STAT3 inhibitors: Antisense ("DUET-101"); RNA silencing ("DUET-202"); and DNA-binding inhibitor ("DUET-301"). The Company may also seek to develop additional drug candidates and identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions.

Products and services

Scopus BioPharma Inc. develops transformational therapeutics for serious diseases with significant unmet medical need.

SCPS key facts

Ticker symbol

SCPS

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

New York, NY, United States

Country of incorporation

US

Year of incorporation

2017

Employees

3

Estimated market cap

$12.6K (as of Apr 11, 2025)

Shares outstanding

42,084,264

Reporting standard

Dark: Alternative Reporting Standard

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Aug 14, 2023)

Scopus Biopharma, Inc. leadership

• Joshua R. Lamstein — Principal Executive Officer
• Robert J. Gibson, CFA — Principal Fin. Officer, Principal Acct. Officer

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with S